I-Semaglutide iyi-polypeptide odokotela abayinikeza ukwelashwa kwesifo sikashukela sohlobo 2.I-FDA igunyaze ukusetshenziswa kwe-Novo Nordisk's Ozempic kanye ne-Rybelsus njengomjovo kanye ngeviki noma njengethebhulethi, ngokulandelana.Umjovo wamasonto onke we-semaglutide onegama lomkhiqizo i-Wegovy usanda kugunyazwa njengokwelashwa kokuncipha kwesisindo.
Ucwaningo olusha olwethulwe ku-European Congress on Obesity yalo nyaka (ECO2023, Dublin, 17-20 May) lubonisa ukuthi i-semaglutide yomuthi wokukhuluphala iyasebenza ekwehleni kwesisindo esifundweni sezwe langempela sonyaka ongu-1.Ucwaningo olwenziwe nguDkt Andres Acosta noDkt Wissam Ghusn, iPrecision Medicine for Obesity Programme eMayo Clinic, eRochester, MN, USA kanye nozakwabo.
I-Semaglutide, i-glucagon-like peptide-1 (GLP-1) receptor agonist, umuthi wakamuva ovunyelwe yi-FDA wokulwa nokukhuluphala.Ibonise imiphumela ebalulekile yokulahlekelwa kwesisindo ezivivinyweni eziningi zesikhathi eside ezingahleliwe zomtholampilo kanye nezifundo zesikhathi esifushane zomhlaba wangempela.Kodwa-ke, kuncane okwaziwayo ngokuncipha kwesisindo kanye nemiphumela yezinqubo ze-metabolic ezifundweni zomhlaba wangempela zamaphakathi nethemu.Kulolu cwaningo, abalobi bahlole imiphumela yokulahlekelwa kwesisindo ehambisana ne-semaglutide ezigulini ezinokukhuluphala ngokweqile nokukhuluphala kanye nangaphandle kohlobo lwe-2 yesifo sikashukela (T2DM) ekulandeleni konyaka we-1.
Benza i-retrospective, i-multicentre (i-Mayo Clinic Hospitals: i-Minnesota, i-Arizona, ne-Florida) ukuqoqwa kwedatha ekusetshenzisweni kwe-semaglutide yokwelapha ukukhuluphala.Bahlanganisa iziguli ezine-index mass body (BMI) ≥27 kg / m2 (isisindo esiningi ngokweqile kanye nazo zonke izigaba ze-BMI eziphakeme) ezibekwe ama-subcutaneous injection ye-semaglutide yamasonto onke (izilinganiso 0.25, 0.5, 1, 1.7, 2, 2.4mg; Nokho iningi lalikhona umthamo omkhulu 2.4mg).Abazibandakanyi iziguli eziphuza eminye imishanguzo yokukhuluphala, ezake zahlinzwa ukukhuluphala ngokweqile, ezinomdlavuza nezizithwele.
Iphuzu lokugcina eliyinhloko laliyiphesenti lokulahlekelwa kwesisindo somzimba (TBWL%) ngonyaka ongu-1.Amaphuzu okugcina esibili ahlanganisa ingxenye yeziguli ezithola ≥5%, ≥10%, ≥15%, kanye ≥20% TBWL%, ushintsho kumingcele ye-metabolic kanye nenhliziyo nemithambo yegazi (umfutho wegazi, i-HbA1c [i-hemoglobin ye-glycated, isilinganiso sokulawula ushukela egazini], i-glucose yokuzila namafutha egazi), i-TBWL% yeziguli ezine-T2DM nezingenayo, kanye nemvamisa yemiphumela emibi phakathi nonyaka wokuqala wokwelashwa.
Ingqikithi yeziguli ezingama-305 zifakiwe ekuhlaziyweni (73% abesifazane, iminyaka yobudala engama-49, 92% abamhlophe, kusho i-BMI 41, 26% ne-T2DM).Izici eziyisisekelo kanye nemininingwane yokuvakasha kokuphathwa kwesisindo kuvezwa kuThebula 1 elingaphelele.Kulo lonke iqembu, isilinganiso se-TBWL% sasingu-13.4% ngonyaka ongu-1 (ezigulini eziyi-110 ezazinedatha yesisindo ngonyaka ongu-1).Iziguli ezine-T2DM zine-TBWL ephansi ye-10.1% yeziguli ezingu-45 ze-110 ezinedatha ngonyaka ongu-1, uma kuqhathaniswa nalabo abangenayo i-T2DM ye-16.7% yeziguli ezingu-65 ze-110 ezinedatha ngonyaka ongu-1.
Iphesenti leziguli ezilahlekelwe ngaphezu kuka-5% wesisindo somzimba wazo lalingu-82%, ngaphezulu kuka-10% kwaba ngu-65%, ngaphezu kuka-15% kwaba ngu-41%, kanti ngaphezu kuka-20% kwaba ngu-21% ngonyaka owodwa.Ukwelashwa kwe-Semaglutide nakho kwehle kakhulu umfutho wegazi we-systolic ne-diastolic nge-6.8 / 2.5 mmHg;i-cholesterol ephelele ngo-10.2 mg/dL;I-LDL ka-5.1 mg/dL;kanye nama-triglycerides angu-17.6 mg/dL.Ingxenye yeziguli yaba nemiphumela engemihle ehlobene nokusetshenziswa kwemithi (154/305) okubikwa kakhulu ukuthi isicanucanu (38%) kanye nesifo sohudo (9%) (Figure 1D).Imiphumela engemihle kakhulu yayimnene ingaphazamisi izinga lempilo kodwa ezimweni ezingu-16 iholele ekumisweni kwemithi.
Ababhali baphetha ngokuthi: "I-Semaglutide ihlotshaniswe nokulahlekelwa kwesisindo esibalulekile kanye nokuthuthukiswa kwemingcele ye-metabolic ngonyaka we-1 esifundweni sezwe sangempela samasayithi amaningi, okubonisa ukuphumelela kwayo ekwelapheni ukukhuluphala, ezigulini ezine-T2DM nangaphandle."
Ithimba le-Mayo lilungiselela eminye imibhalo yesandla eminingana ephathelene ne-semaglutide, kuhlanganise nemiphumela yesisindo ezigulini ezinesisindo sokuphindaphinda ngemuva kokuhlinzwa kwe-bariatric;imiphumela yokuncipha kwesisindo ezigulini ebezikweminye imithi yokulwa nokukhuluphala ngaphambilini uma kuqhathaniswa nalabo ababengekho.
Isikhathi sokuthumela: Sep-20-2023